Clinical trial

Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision

NCT06281769

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DIAGNOSTIC_TEST · Unmapped registry intervention 3D multi-parametric ultrasound targeted biopsy pathway using PcaVision Find medicine records · Find other trials using this name

DIAGNOSTIC_TEST · Unmapped registry intervention MRI targeted biopsy pathway Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-02-26

PhaseNA

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

3D multi-parametric ultrasound targeted biopsy pathway using PcaVisionDIAGNOSTIC_TEST

MRI targeted biopsy pathwayDIAGNOSTIC_TEST

Sponsors & collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)lead sponsor

Angiogenesis Analyticscollaborator

Mapped research locations

AmsterdamNetherlands1 RotterdamNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06281769 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.